TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16328375

Group type: EXPERIMENTAL
Intervention: Galantamine (GAL)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 12599088

Group type: EXPERIMENTAL
Intervention: Zidovudine and lamivudine plus nelfinavir or nevirapine
Number of subjects: 127
Study: 11515628

Group type: EXPERIMENTAL
Intervention: Troxipide at concentrations of 10-6 to 10-4 M
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Troxipide
Number of subjects: 0
Study: 9160413

Group type: EXPERIMENTAL
Intervention: Formoterol 24 micrograms
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salbutamol 400 micrograms
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1602034

Group type: EXPERIMENTAL
Intervention: Metronidazole, 250 mg 3 x a day for 1 week
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (positive-control)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 33
Study: 3912193

Group type: EXPERIMENTAL
Intervention: Cyclacillin with Amoxicillin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cyclacillin with Ampicillin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cyclacillin with Bacampicillin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Bacampicillin
Number of subjects: 14
Study: 29395502

Group type: EXPERIMENTAL
Intervention: Docetaxel 75mg/m2 every 3 weeks for six cycles (Arm A)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Surveillance (Arm B)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Docetaxel (Arm A)
Number of subjects: 459
Study: 27521808

Group type: EXPERIMENTAL
Intervention: Basic public reporting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (smart phone-based application)
Number of subjects: 0
Study: 25906700

Group type: EXPERIMENTAL
Intervention: MOM intervention (office-based written and verbal targeted depression education and motivational messages, plus a semistructured telephone booster 2 days later)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control intervention (nontargeted written and verbal messages, plus an attention control telephone survey 2 days later)
Number of subjects: 104
Study: 22944095

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 200
Study: 20472815

Group type: EXPERIMENTAL
Intervention: Statin therapy (mean treatment duration of 25.6 months)
Number of subjects: 3806

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 3806

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 3806
Study: 18055274

Group type: EXPERIMENTAL
Intervention: Telephone-delivered intervention for physical activity and dietary change (18 calls over 12 months)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 434
Study: 15705978

Group type: EXPERIMENTAL
Intervention: EUS-guided FNA with real-time RT-PCR
Number of subjects: 87

Group type: COMPARATOR
Intervention: Normal control FNA specimens from patients without cancer
Number of subjects: 87
Study: 12915698

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No drug treatment (control group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Buformine treatment (n=10)
Number of subjects: 30
Study: 10591092

Group type: EXPERIMENTAL
Intervention: Postoperative cardiac complications (major and minor)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Postoperative cardiac complications
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Preoperative diuretics
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Increased time during cross-clamping
Number of subjects: 248
Study: 8713688

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg) +/− Indapamide (2.5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 60
Study: 1714021

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 7100360

Group type: EXPERIMENTAL
Intervention: High feedback ultrasound (monitor screen visible, shown fetal size, shape, and movement)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Low feedback ultrasound (screen not seen, specific verbal feedback denied)
Number of subjects: 129
Study: 30804274

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral steroids for 6 months
Number of subjects: 0
Study: 29069003

Group type: EXPERIMENTAL
Intervention: Group A: 250 mL 20% mannitol and 1 L 0.9% saline orally at 05:00 hours on the day of the procedure.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Group B: Same preparation as Group A, taken at 20:00 on the day before, and at 05:00 on the day of CE; in addition, 20 mL oral simethicone taken 30 minutes before CE.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Group C: Identical to Group B, except patients fasted for 3 days and took 3 g senna orally 3 times daily before CE.
Number of subjects: 180
Study: 26220784

Group type: EXPERIMENTAL
Intervention: Internet Decision Aid
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: DVD Decision Aid
Number of subjects: 155
Study: 24846362

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 22014309

Group type: EXPERIMENTAL
Intervention: Mailed personalized feedback regarding alcohol consumption
Number of subjects: 244

Group type: COMPARATOR
Intervention: No feedback (Control group)
Number of subjects: 244
Study: 19506821

Group type: EXPERIMENTAL
Intervention: DSS-optimized plans
Number of subjects: 10
Study: 17062760

Group type: EXPERIMENTAL
Intervention: Single-dose bexarotene (400 mg/m2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 15313870

Group type: EXPERIMENTAL
Intervention: Pollen blocker cream applied 4 times daily for 9 days
Number of subjects: 91

Group type: COMPARATOR
Intervention: Carboxymethylcellulose in gel (placebo) applied 4 times daily for 9 days
Number of subjects: 91
Study: 11772856

Group type: EXPERIMENTAL
Intervention: Mother-infant intervention delivered by trained community workers
Number of subjects: 32

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mother-infant intervention
Number of subjects: 32
Study: 11181682

Group type: EXPERIMENTAL
Intervention: Oral docetaxel 75 mg/m(2) with CsA 15 mg/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral docetaxel 75 mg/m(2) without CsA
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intravenous docetaxel 100 mg/m(2)
Number of subjects: 14
Study: 9037321

Group type: EXPERIMENTAL
Intervention: ACE inhibitor treatment (fosinopril)
Number of subjects: 96
Study: 8316680

Group type: EXPERIMENTAL
Intervention: Thioridazine 1.25 mg/kg/day
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Thioridazine 2.5 mg/kg/day
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Thioridazine plus visual screening
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Visual screening alone
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 3
Study: 3528988

Group type: EXPERIMENTAL
Intervention: Methadone (n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Morphine (n = 9)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both Methadone and Morphine
Number of subjects: 18
Study: 31216898

Group type: EXPERIMENTAL
Intervention: Culturally adapted depression intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31612329

Group type: EXPERIMENTAL
Intervention: Preoperative S-1 plus oxaliplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of immune checkpoint inhibitors to cytotoxic chemotherapy
Number of subjects: 0
Study: 30167814

Group type: EXPERIMENTAL
Intervention: RAPID3
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PsAID9
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PG-arthritis
Number of subjects: 47
Study: 27663039

Group type: EXPERIMENTAL
Intervention: Low-osmolar diet (low-sodium [1,500mg/d], low-protein [0.8g per kilogram of body weight]) and adjusted water intake to achieve urine osmolality ≤ 280mOsm/kg water
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-osmolar diet and adjusted water intake
Number of subjects: 34
Study: 24994482

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 21311506

Group type: EXPERIMENTAL
Intervention: SBWL+TECH
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SBWL
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: TECH
Number of subjects: 51

Group type: COMPARATOR
Intervention: Retention rates
Number of subjects: 51
Study: 21111986

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACEi)
Number of subjects: 4291

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 4291

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 4291
Study: 18688284

Group type: EXPERIMENTAL
Intervention: AEB071 (PKC inhibitor), administered as single and multiple ascending oral doses to patients with psoriasis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AEB071 (PKC inhibitor), administered as single doses to healthy volunteers.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AEB071 (PKC inhibitor), administered to patients with psoriasis.
Number of subjects: 0
Study: 15972028

Group type: EXPERIMENTAL
Intervention: Atrial pacing-induced increases in heart rate up to 150 bpm
Number of subjects: 18
Study: 12872392

Group type: EXPERIMENTAL
Intervention: Fuzheng Yiliu Granule (FYG) in addition to conventional chemotherapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional chemotherapy alone
Number of subjects: 55
Study: 10344610

Group type: COMPARATOR
Intervention: 10 mg of amphotericin B per liter of sterile water as continuous irrigation for 72 hours at the rate of 42 mL/hr
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 50 mg of amphotericin B per liter of sterile water as continuous irrigation for 72 hours at the rate of 42 mL/hr
Number of subjects: 28
Study: 8596486

Group type: EXPERIMENTAL
Intervention: Aerobic training (12 weeks, three times per week)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Weight training (12 weeks, three times per week)
Number of subjects: 18
Study: 1722769

Group type: EXPERIMENTAL
Intervention: Bleomycin treatment (15 mg by continuous infusion two times a week during 5 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Classical radiation treatment with telecobalt‐therapy 50 Gy/25 fractions plus 32 Gy/4 fractions (Cathetron)
Number of subjects: 55
Study: 31854054

Group type: EXPERIMENTAL
Intervention: Intensive group (individualized nutritional treatment)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 128
Study: 31139911

Group type: EXPERIMENTAL
Intervention: Patients who visited 3 different physicians before surgery (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patients who visited ≥ 4 physicians before surgery (Group 2)
Number of subjects: 100
Study: 29202786

Group type: EXPERIMENTAL
Intervention: PERFECTED enhanced recovery intervention (PERFECT-ER)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 400
Study: 23711244

Group type: EXPERIMENTAL
Intervention: Mepilex(®) Border Sacrum and Mepilex(®) Heel dressings applied in the emergency department and maintained throughout ICU stay
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Mepilex(®) Border Sacrum and Mepilex(®) Heel dressings
Number of subjects: 440
Study: 25163905

Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 1643
Study: 21605175

Group type: EXPERIMENTAL
Intervention: Once daily application of betamethasone valerate 0.1% corticosteroid cream
Number of subjects: 44

Group type: COMPARATOR
Intervention: Twice daily application of betamethasone valerate 0.1% corticosteroid cream
Number of subjects: 44

Group type: COMPARATOR
Intervention: Urea-containing moisturizer (substituted for corticosteroid cream in the morning)
Number of subjects: 44
Study: 19016342

Group type: EXPERIMENTAL
Intervention: 10 mg BH(4)/kg body weight
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 20 mg BH(4)/kg body weight
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 30 mg BH(4)/kg body weight
Number of subjects: 17
Study: 17283006

Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 205
Study: 15028243

Group type: EXPERIMENTAL
Intervention: [(11)C]L‐deprenyl (DEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: [(11)C]clorgyline (CLG)
Number of subjects: 0
Study: 11597936

Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy (niacin 2.5 g/d, lovastatin 40 mg/d, colestipol 20 g/d) for 10 years
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (untreated CAD patients)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 9585292

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine
Number of subjects: 10
Study: 8033381

Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole gel
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 2586436

Group type: EXPERIMENTAL
Intervention: OK-432 intratumoral injection (group A)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 395
Study: 195411

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (COMB)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (BACO)
Number of subjects: 35
Study: 29635520

Group type: EXPERIMENTAL
Intervention: BRYAN® Cervical Disc arthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined BRYAN® and Prestige disc groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined ACDF groups
Number of subjects: 0
Study: 28863555

Group type: EXPERIMENTAL
Intervention: Bilateral hearing aid users with broad binaural pitch fusion
Number of subjects: 0
Study: 25627340

Group type: EXPERIMENTAL
Intervention: GPi deep brain stimulation (DBS)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: STN deep brain stimulation (DBS)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Both GPi and STN DBS
Number of subjects: 235
Study: 23969797

Group type: EXPERIMENTAL
Intervention: Oxytocin plus uterine massage
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Oxytocin only
Number of subjects: 1170
Study: 21954647

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined guidance of ultrasound and nerve stimulator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nerve stimulator guidance
Number of subjects: 0
Study: 19386740

Group type: EXPERIMENTAL
Intervention: High-Fat (H-F) diet (30% of energy as carbohydrate and 55% as fat)
Number of subjects: 7

Group type: COMPARATOR
Intervention: High-Carbohydrate (H-CHO) diet (60% of energy as carbohydrate and 25% as fat)
Number of subjects: 7
Study: 16414235

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m² and Docetaxel 35 mg/m²
Number of subjects: 68
Study: 15319108

Group type: EXPERIMENTAL
Intervention: Bioabsorbable pins (PLLA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Kirschner wires
Number of subjects: 62
Study: 11175583

Group type: EXPERIMENTAL
Intervention: N‐methyl‐glucamine (GL)
Number of subjects: 63

Group type: COMPARATOR
Intervention: BP88 Sodium Stibogluconate (SS)
Number of subjects: 63
Study: 9274702

Group type: EXPERIMENTAL
Intervention: GHRH (100 micrograms)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: GHRP-6 (1 microgram/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: GHRH + GHRP-6
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 25
Study: 8361250

Group type: EXPERIMENTAL
Intervention: Contract ADHC
Number of subjects: 163

Group type: COMPARATOR
Intervention: VA-ADHC
Number of subjects: 163

Group type: COMPARATOR
Intervention: Customary care
Number of subjects: 163
Study: 3718600

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH) preparations A (tablet) and B (buffered solution) containing 50 mg DPH-HCl
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference preparation C containing 31 mg DPH-HCl and 23 mg 8-chlorotheophylline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination with 8-chlorotheophylline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pharmacodynamic measurements of vigilance
Number of subjects: 12
Study: 31969275

Group type: EXPERIMENTAL
Intervention: Multidomain intervention (four home visits and 12 telephone calls over 12 weeks, incorporating physical activity, healthy diet, social activity, and brief cognitive restructuring)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 78
Study: 30938120

Group type: EXPERIMENTAL
Intervention: LMA protector
Number of subjects: 143

Group type: COMPARATOR
Intervention: LMA traditional
Number of subjects: 143
Study: 27834191

Group type: EXPERIMENTAL
Intervention: Video decision aid and text message reminder
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study: 26861425

Group type: EXPERIMENTAL
Intervention: Permethrin 5% cream
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lindane 1% lotion
Number of subjects: 120
Study: 23106243

Group type: EXPERIMENTAL
Intervention: 400 μg misoprostol
Number of subjects: 310

Group type: COMPARATOR
Intervention: 800 μg misoprostol
Number of subjects: 310
Study: 21597409

Group type: EXPERIMENTAL
Intervention: Piracetam 12 g
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: COMPARATOR
Intervention: Both groups (Piracetam and Placebo)
Number of subjects: 88
Study: 18155382

Group type: EXPERIMENTAL
Intervention: Rescue hook
Number of subjects: 20

Group type: COMPARATOR
Intervention: Trauma scissors
Number of subjects: 20
Study: 16675186

Group type: EXPERIMENTAL
Intervention: ProSeal LMA (MLP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Classic laryngeal mask airway (MLC)
Number of subjects: 120
Study: 15010152

Group type: EXPERIMENTAL
Intervention: Silicone tube nerve repair
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine microsurgical repair
Number of subjects: 30
Study: 11682384

Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study: 9129038

Group type: EXPERIMENTAL
Intervention: Standard dose cytosine arabinoside and daunomycin + rhG‐CSF
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: MDR1(+) secondary AML patients with unfavorable cytogenetics
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Unfavorable cytogenetics
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: MDR1 expression
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Secondary AML
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Resistant disease
Number of subjects: 211
Study: 7948961

Group type: EXPERIMENTAL
Intervention: C2T (2 g ceftazidime every 8 h plus 5 mg/kg/day tobramycin)
Number of subjects: 150

Group type: COMPARATOR
Intervention: C1T (1 g ceftazidime every 8 h plus 5 mg/kg/day tobramycin)
Number of subjects: 150
Study: 3361022

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg/day during the first 3 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Not receiving dexamethasone (control group)
Number of subjects: 25
Study: 31915047

Group type: EXPERIMENTAL
Intervention: Second Propess® placement followed by oxytocin (Syntocinon®) if necessary
Number of subjects: 360

Group type: COMPARATOR
Intervention: Direct oxytocin injection
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Second Propess® placement
Number of subjects: 360
Study: 29098341

Group type: EXPERIMENTAL
Intervention: Roflumilast 100 μg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27112113

Group type: EXPERIMENTAL
Intervention: Adapted Motivational Interviewing (AMI)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 51
Study: 25325892

Group type: EXPERIMENTAL
Intervention: Femtosecond laser group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual group
Number of subjects: 20
Study: 22545755

Group type: EXPERIMENTAL
Intervention: Multi-component program including classroom curriculum, school environment support, family involvement, and fun programs/events.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Usual health and physical education curriculum with no additional intervention program.
Number of subjects: 8
Study: 20338496

Group type: EXPERIMENTAL
Intervention: Optimal medical therapy
Number of subjects: 2287
Study: 18250126

Group type: EXPERIMENTAL
Intervention: MELD score > or = 18
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: MELD score > or = 18 and > or = 4 units of PRBCs transfused
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: MELD score > or = 18 and active bleeding at index endoscopy
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Variceal re‐bleeding
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: MELD score
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Units of packed red blood cells (PRBCs) transfused in the first 24 h
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Clot on a varix
Number of subjects: 256